Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 128,578

Document Document Title
WO/2017/190682A1
The present invention discloses a novel crystalline form E of a tafamidis methylglucamine salt, and a preparation method and application thereof. When compared to other known crystalline forms, the new crystalline form provided in the in...  
WO/2017/191351A1
The present invention relates to delayed-release methylphenidate tablets characterized in that they are provided with a release-controlling layer comprising a combination of an enteric polymer and a hydrophobic agent. These tablets have ...  
WO/2017/191838A1
The invention provides a safe and stable plasmalogen, a formulation thereof, and a method for assessing presymptomatic dementia. More specifically, the invention comprises: a supplement or a foodstuff as a processed product for the mitig...  
WO/2017/192930A1
The invention provides substituted imidazo[1,2-b]pyridazine compounds, substituted imidazo[1,5-b]pyridazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and comp...  
WO/2017/192538A1
The invention provides TrkB agonist antibodies or antigen-binding fragments that specifically enhance TrkB signaling activities. The invention also provides therapeutic methods of using such antibodies for promoting survival and regenera...  
WO/2017/192841A1
The invention provides methods of treatment and combination therapies using heterobicyclic and related compounds that activate Gcase, such as in the treatment of endometriosis and Parkinson's disease. An exemplary heterobicyclic compound...  
WO/2017/192906A1
The present application provides methods for treating human subjects suffering from Rett Syndrome by administering PKC activators, for example, bryostatin 1, other bryostatins and bryologs. The present disclosure provides, according to c...  
WO/2017/192931A1
The invention provides substituted imidazo[1,2-α]pyridine compounds, substituted imidazo[1,2-α]pyrazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compos...  
WO/2017/191638A1
The instant invention provides methods and compositions which are applicable for modulating, preventing or treating non-clinical and clinical conditions that are associated with composition of mammalian microbiome. Methods and compositio...  
WO/2017/187336A4
The present invention relates to pharmaceutically acceptable complex formulations comprising complexes of Ivacaftor, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the pr...  
WO/2017/185900A1
Provided are a series of crocins compounds and related pharmacological application thereof in prevention and treatment of Alzheimer's disease. The series of crocins compounds are obtained by taking the Chinese herb, namely Gardenia jasmi...  
WO/2017/185959A1
Fused imidazole derivatives having IDO/TDO inhibiting activity and having the structure of formula (I), and a preparation method and use therefor. The series of fused imidazole derivatives has a high degree of inhibiting activity against...  
WO/2017/186686A1
The present invention relates to the use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in patients suffering from a CNS disease, in particular patients with Parkin- son's disease, wherein balance, gait or movem...  
WO/2017/185249A1
The present application provides a peptide comprising an amino acid sequence of YEKLLDTEI (SEQ ID NO: 1) or a functional variant thereof. The peptide is a bioactivee peptide for the treatment of central nervous system injuries. The prese...  
WO/2017/186924A1
Stable crystal forms comprising lithium ions and the conjugate base of an organic acid which is in the form of anhydrous coordination polymer that exhibit improved in vivo performance with respect to lithium carbonate.  
WO/2017/187176A1
The invention relates to the treatment of impulsivity-related disorders, such as a substance-related addiction, a behavioural addiction, relapse to a substance-related or behavioural addiction, a habit or impulsive disorder, an emotional...  
WO/2017/187352A1
The invention relates to a new class of compounds of formula (I) targeting COX-1. The invention also relates to the use of some of such compounds as a tool to investigate the structure and function of the enzyme, in the treatment targeti...  
WO/2017/188403A1
The purpose of the present invention is to provide a new mesenchymal stem cell having excellent therapeutic effects for various diseases, a new pharmaceutical composition containing the mesenchymal stem cell, and methods for preparing th...  
WO/2017/187340A4
The invention is directed to a pharmaceutical combination composition comprising stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Ivacaftor and Lum...  
WO/2017/186919A1
The present invention relates to an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-c arboximioyl chloride, its stereoisomers and the acid addition salts thereof (arimoclomol), fo...  
WO/2017/188457A1
The present invention relates to a synapse formation accelerant and a brain plasticity accelerant that contain CD24-negative mesenchymal stem cells prepared from a patient's own bone marrow fluid, as well as to treatment of dementia, chr...  
WO/2017/186934A1
The invention relates to dipeptidyl peptidase-4 inhibitors, including saxagliptin and sitagliptin, for use in the topical eye treatment and/or prevention of retinal neurodegenerative diseases, in particulardiabetic retinopathyand its ass...  
WO/2017/185899A1
A composition, and a crocins active site extracted from Gardenia jasminoides Ellis, mainly comprising the following ingredients: crocetin di-β-D-gentiobioside, crocetin-β-D-glucopyranosyl-β-D-gentiobioside, crocetin di-β-D-glucopyran...  
WO/2017/188365A1
A medicine for preventing and/or treating multiple sclerosis, particularly pain such as neuropathic pain associated with multiple sclerosis and the like, said medicine containing, as an active ingredient, a compound having an antagonisti...  
WO/2017/189951A1
A method for evaluating a subject's risk of developing glaucoma, or having glaucoma, or having glaucoma that will progress in severity comprising determining from a biological sample from a subject whether the patient has a mitochondrial...  
WO/2017/188260A1
In some embodiments, a composition of matter includes aripiprazole, a metal selected from the group consisting of magnesium, zinc, sodium, lithium, iron, or alloys thereof, or combinations thereof and a copper salt selected from the grou...  
WO/2017/187338A4
The present invention relates to pharmaceutically acceptable complex formulation comprising complexes of Lumacaftor, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the pr...  
WO/2017/189375A1
A chewing gum composition comprising cannabinoids or derivatives thereof and nicotine in the form of nicotine polacrilex is provided. The chewing gum composition is formulated to provide rapid and controlled release of cannabinoids and n...  
WO/2017/187338A1
The present invention relates to pharmaceutically acceptable complex formulation comprising complexes of Lumacaftor, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the pr...  
WO/2017/187340A1
The invention is directed to a pharmaceutical combination composition comprising stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Ivacaftor and Lum...  
WO/2017/187336A1
The present invention relates to pharmaceutically acceptable complex formulations comprising complexes of Ivacaftor, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the pr...  
WO/2017/185250A1
Provided in the present application is a peptide containing the amino acid sequence YEKLTTLDTGGV (SEQ ID NO:1) or a functional variant thereof, the peptide being an active peptide for treating central nervous system injury. Also provided...  
WO/2017/181585A1
The present invention relates to the technical field of medicine, and specifically relates to a PUMA inhibitor, a method for preparation thereof, and a use thereof. The PUMA inhibitor is the compound as shown in (I) or a pharmaceutically...  
WO/2017/181790A1
A neutron capture therapy system for eliminating an amyloid β-protein plaque. The system comprises: a neutron capture therapy device and a compound comprising 10B, wherein the compound can specifically bind to an amyloid β-protein plaq...  
WO/2017/185061A1
The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.  
WO/2017/181811A1
Disclosed are an opctahydroanthracene compound as represented by formula (I) or (II), a preparation method for same, and uses of same, which provides great therapeutic effects for tumors and neurodegenerative diseases and is prepared mai...  
WO/2017/185073A1
The present invention provides methods and compositions for improving episodic memory and treating dementia.  
WO/2017/184871A1
The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions...  
WO/2017/185083A1
Methods useful for treating X-linked adrenoleukodystrophy are provided.  
WO/2017/183734A1
Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt the...  
WO/2017/185010A1
The present invention relates to compositions and methods of treating lysosomal storage diseases and methods of using trehalose.  
WO/2017/182464A1
The present invention relates to compounds of formula (I); which are capable of inhibiting the 11-beta-hydroxysteroid dehydrogenase type 1 (11- beta-HSD1), to processes for preparing these compounds, to pharmaceutical compositions compri...  
WO/2017/184871A9
The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions...  
WO/2017/185087A1
Methods useful for treating X-linked adrenoleukodystrophy are provided.  
WO/2017/183736A1
Dopamine-producing neural precursor cells are produced by: producing a cell population containing Corin and/or Lrtm1 positive cells via steps (1) and (2) as will be shown below; collecting the Corin and/or Lrtm1 positive cells from the c...  
WO/2017/183970A1
The invention concerns nutritional compositions comprising linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA/ALA weight ratio in the range of 0.1 –12 that have a beneficial effect on preventing early life stress induced decline...  
WO/2017/182688A1
The present invention relates to a powdered composition obtained from an extract of saffron stigmas, characterized in that it comprises from 0.03% to 1 % dry weight of safranal; and at least 3.48 % dry weight of crocins, encompassing the...  
WO/2017/181791A1
Provided is an application of a compound comprising 10B for preparing a pharmaceutical product specifically binding an amyloid β-protein. After the pharmaceutical product specifically binding the amyloid β-protein binds the amyloid β-...  
WO/2017/182945A1
The present disclosure relates to fluorescent compounds with large Stokes' shift. This disclosure also relates to the, production methods and use of said fluorescent compounds for cellular labelling and in vivo imaging for use in medicin...  
WO/2017/183956A1
The invention concerns nutritional compositions comprising linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA/ ALA weight ratio in the range of 0.1 - 12 that have a beneficial effect on preventing early life stress induced decline...  

Matches 501 - 550 out of 128,578